Comparison of twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) with once-daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabetic agents

被引：0

|

作者：

Raskin, P

Rojas, P

Allen, E

机构：

来源：

DIABETES | 2004年 / 53卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A143 / A143

页数：1

相关论文

共 50 条

[1] Serum 1,5-anhydroglucitol as a marker of glycemic control in subjects receiving twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) vs. once-daily insulin glargine in patients with type 2 DM on oral antidiabetic agents
Moses, A
Raskin, P
Hu, P
Allen, E
DIABETES, 2005, 54 : A96 - A96
[2] Comparison of treatment satisfaction of twice-daily BIAsp 70/30 with once-daily insulin glargine in patients with type 2 diabetes
Brod, M
Lammert, M
Raskin, P
DIABETES, 2005, 54 : A114 - A114
[3] Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes
Tamemoto, Hiroyuki
Ikoma, Aki
Saitoh, Takako
Ishikawa, San-E
Kawakami, Masanobu
DIABETES TECHNOLOGY & THERAPEUTICS, 2007, 9 (03) : 246 - 253
[4] A COMPARISON OF TWICE-DAILY BIPHASIC INSULIN ASPART 70/30 AND ONCE-DAILY INSULIN GLARGINE IN PERSONS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON BASAL INSULIN AND ORAL THERAPY: A RANDOMIZED, OPEN-LABEL STUDY
Ligthelm, Robert J.
Gylvin, Titus
DeLuzio, Tony
Raskin, Philip
ENDOCRINE PRACTICE, 2011, 17 (01) : 41 - 50
[5] Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
Kann, P. H.
Wascher, T.
Zackova, V.
Moeller, J.
Medding, J.
Szocs, A.
Mokan, M.
Mrevlje, F.
Regulski, M.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (09) : 527 - 532
[6] Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
Kilo, C
Mezitis, N
Jain, R
Mersey, J
McGill, J
Raskin, P
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (06) : 307 - 313
[7] The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial
Linjawi, Sultan
Sothiratnam, Radhakrishna
Sari, Ramazan
Andersen, Henning
Hiort, Line Conradsen
Rao, Paturi
PRIMARY CARE DIABETES, 2015, 9 (05) : 370 - 376
[8] Once daily initiation with biphasic insulin aspart 30 (BIAsp 30) versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs - a randomized controlled trial
Franek, E.
Kalra, S.
Pesic, M.
Smahelova, A.
Thomsen, H.
Strojek, K.
DIABETOLOGIA, 2009, 52 : S93 - S93
[9] Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): Comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride
Ebato, C.
Shimizu, T.
Arakawa, M.
Mita, T.
Fujitani, Y.
Watada, H.
Kawamori, R.
Hirose, T.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2009, 86 (01) : 31 - 36
[10] Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
Valensi, Paul
DIABETES METABOLIC SYNDROME AND OBESITY, 2009, 2 : 61 - 71

← 1 2 3 4 5 →